Shares of drugmaker InterMune have more than doubled in premarket trading after a European advisory panel backed the company’s experimental lung treatment Esbriet (pirfenidone), something the biotech failed to accomplish in the U.S.

Continue reading InterMune Lung Drug Is Backed by European Panel, Shares Double

InterMune Lung Drug Is Backed by European Panel, Shares Double originally appeared on DailyFinance on Fri, 17 Dec 2010 09:30:00.

Filed Under: Company News, Health Care, Stocks in the News